Analysts Are Neutral on These Healthcare Stocks: SAGE Therapeutics (SAGE), Adverum Biotechnologies (ADVM)
Adverum Biotechnologies Analyst Ratings
Chardan Capital Reiterates Buy on Adverum Biotechnologies, Maintains $4 Price Target
Adverum Biotechnologies Analyst Ratings
RBC Capital Maintains Sector Perform on Adverum Biotechnologies, Lowers Price Target to $2
RBC Cuts Price Target on Adverum Biotechnologies to $2 From $3, Keeps Sector Perform, Speculative Risk
Adverum Biotechnologies (ADVM) Initiated With a Hold at RBC Capital
Adverum Biotechnologies (ADVM) Receives a Buy From TD Cowen
Adverum Biotechnologies Analyst Ratings
Analysts Have Conflicting Sentiments on These Healthcare Companies: Healthequity (HQY), Adverum Biotechnologies (ADVM) and Edwards Lifesciences (EW)
Analysts Offer Insights on Healthcare Companies: InMode (INMD), Ocular Therapeutix (OCUL) and Adverum Biotechnologies (ADVM)
Promising Developments in Adverum Biotechnologies' Gene Therapy Candidate, Ixo-Vec, Drive Graig Suvannavejh's Bullish Rating
Truist Financial Remains a Buy on Adverum Biotechnologies (ADVM)
Analysts Conflicted on These Healthcare Names: Xenon (XENE), Adverum Biotechnologies (ADVM) and 4D Molecular Therapeutics (FDMT)
RBC Capital Reaffirms Their Hold Rating on Adverum Biotechnologies (ADVM)
Adverum Biotechnologies' Potential Outperformance: A Buy Rating Based on Ixo-Vec Progress and OPTIC Study Results
Analysts Offer Insights on Healthcare Companies: Sarepta Therapeutics (SRPT), Adverum Biotechnologies (ADVM) and Alignment Healthcare (ALHC)
Analysts Offer Insights on Healthcare Companies: CVS Health (CVS), IGM Biosciences (IGMS) and Adverum Biotechnologies (ADVM)
Truist Securities Reiterates Buy on Adverum Biotechnologies, Maintains $6 Price Target
Adverum Biotechnologies Analyst Ratings
No Data